Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma-cell disorder present in approximately 5% of the general population over the age of 50 years. MGUS is characterized ...

An international team of scientists has generated a new ring-shaped protein nanomaterial capable of strongly binding to and neutralising the SARS-CoV2 ...

This represents Alector's second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in ...

A copy of the presentation materials can be accessed on the “ Publication ” section of the Company’s website at www.bioatla.com once the presentation has concluded.

A copy of the presentation materials can be accessed on the “ Publication ” section of the Company’s website at www.bioatla.com once the presentation has concluded.

ProMIS Neurosciences, Inc. , a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Slanix ...

Genetic screening can mean that people at risk of type 1 diabetes get earlier treatment and better outcomes This article is ...

Newseria nie ponosi odpowiedzialności za treści oraz inne materiały (np. infografiki, zdjęcia) przekazywane w „Biurze Prasowym”, których autorami są zarejestrowani użytkownicy tacy jak agencje PR, ...

RATIONALE-307 and -312 – reinforce the PD-1 inhibitor’s proven clinical benefit in both NSCLC and ES-SCLCEarly data from investigational HPK1 inhibitor BGB-26808, in combination with TEVIMBRA, show ...

As tick season worsens each year in the Northeast and cases of Lyme disease trend upward, researchers at the UMass Chan Medical School say they've reached a new milestone in developing a potential ...

Clinical Breakthroughs Converge As Immunotherapy Market Surges Past $136 Billion - Financial News Media. Issued on behalf of GT Biopharma, Inc. Vancouver, BC – October 6, 2025 – USA News Group News ...